Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa-Reference-Cited by-同舟云学术

Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa

Published:2017-09 Issue:9 Volume:137 Page:1842-1849
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Atanasova Velina S.,Jiang Qiujie,Prisco Marco,Gruber Christina,Piñón Hofbauer Josefina,Chen Mei,Has Cristina,Bruckner-Tuderman Leena,McGrath John A.,Uitto Jouni,South Andrew P.

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference49 articles.

1. Novel small molecules potentiate premature termination codon readthrough by aminoglycosides;Baradaran-Heravi;Nucleic Acids Res,2016

2. Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa;Bremer;Mol Ther Nucleic Acids,2016

3. High-affinity binding of the NC1 domain of collagen VII to laminin 5 and collagen IV;Brittingham;Biochem Biophys Res Commun,2006

4. Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain;Bruckner-Tuderman;J Cell Biol,1995

5. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa;Chen;Nat Genet,2002

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa;Scientific Reports;2024-08-16

2. Targeting the Complexity of In Vitro Skin Models: A Review of Cutting-Edge Developments;Journal of Investigative Dermatology;2024-08

3. Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going;Experimental Dermatology;2024-03

4. Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons;Pharmaceuticals;2024-02-28

5. Neue Lokal- und Systemtherapien bei Epidermolysis bullosa;hautnah;2024-02-01